Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive data from a 12-week Phase 2a ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Taking the ‘GLP-1 receptor agonist’ class of anti-obesity drugs is related with lower rates of post-surgery complications in ...

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low ...

The results also showed that the patients taking the GLP-1 RA drugs have a 12 per cent lower risk of hospital re-admission ...

Patients taking the anti-obesity drugs had about 12% lower risk of hospital re-admission within a month of surgery, compared ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...